PwC's Next in Health

Glenn Hunzinger, PwC's US Health Industries Leader, speaks with James Woods, PwC's US MedTech Leader, about the forces shaping MedTech dealmaking in 2026. Despite capital market pressures, supply chain challenges, and geopolitical uncertainty, companies continue to invest in innovation, portfolio transformation, and growth opportunities. The conversation explores where capital is flowing...

Glenn Hunzinger, PwC's US Health Industries Leader, speaks with Dan Farrell, PwC's Health Services Deals Leader, about the forces shaping health services dealmaking in 2026. Despite ongoing reimbursement uncertainty, rising medical costs, and operational pressures, investors continue to deploy capital into assets with strong fundamentals and clear value creation opportunities. The conver...

Glenn Hunzinger, PwC's US Health Industries Leader, speaks with Dan Farrell, PwC's Health Services Deals Leader, about the forces shaping health services dealmaking in 2026. Despite ongoing reimbursement uncertainty, rising medical costs, and operational pressures, investors continue to deploy capital into assets with strong fundamentals and clear value creation opportunities. The conver...

As the 2026 midterm elections approach, healthcare leaders are asking whether this is just another policy cycle or a more pivotal moment in an increasingly complex and fragmented landscape. In this episode of PwC’s Next in Health, Glenn Hunzinger speaks with Kelly Griffin and Philip Sclafani about how shifting policy dynamics, persistent cost pressures, and rapid industry transformation are reshap...

With $50 billion flowing through the Rural Health Transformation Program (RHTP), healthcare leaders are questioning whether this marks short term stabilization or a real opportunity to redesign rural care. In this episode of PwC’s Next in Health, Glenn Hunzinger speaks with Thom Bales and Jill Olmstead about how states are deploying funds, how accountability is shaping execution, and what sustaina...

From the JPM Healthcare Conference in San Francisco, Glenn Hunzinger, PwC’s Health Industries Leader, speaks with Jeremy Gelber, Partner at Vitruvian Partners, and Claire Love, Principal in PwC’s Deals Strategy practice to explore where healthcare investment momentum is building for 2026, how technology is reshaping value creation, and what investors are watching as care models, consumer behavior,...

From the JPM Healthcare Conference in San Francisco, Glenn Hunzinger brings together Sunil Patel of Merck and Sumit Khedekar of Citigroup for a conversation about where growth in the pharmaceutical and biotech industry is headed over the next five to ten years. They explore how scientific innovation, global sources of capital and talent, and a more forward looking approach to risk taking are shapi...

Join Glenn Hunzinger and James Woods as they discuss what to expect for medtech dealmaking in 2026, including why buyers are poised to return, how technology is reshaping portfolios, and where investors are focusing to drive future growth. Discussion highlights: Medtech M&A is expected to rebound in 2026 as market conditions improve and capital remains available Buyers are staying selective, p...

Tune in as Glenn Hunzinger and Roel van den Akker share their outlook for pharmaceutical and life sciences dealmaking in 2026. They discuss improving market conditions, innovation driven growth, and how upcoming loss of exclusivity is shaping deal strategy.    Discussion highlights:  Strong innovation, healthy balance sheets, and improving capital markets support a positive outlook for 2026  M&amp...

Join Glenn Hunzinger and Dan Farrell as they discuss why 2026 could mark a rebound year for health services dealmaking—driven by higher-quality assets, improving market conditions, and the growing role of technology and AI. They explore how investors are rethinking value creation, from tech-enabled care models to carve-outs and IPOs.   Discussion highlights: Stronger earnings, cash flows, and tech...

What will healthcare look like a decade from now? Host Glenn Hunzinger is joined by Greg Rotz, Pharmaceutical and Life Sciences Advisory Leader and Thom Bales, Principal, Health Services Advisory Leader, as they dive into the future of health—one driven by smarter tech, empowered consumers, and breakthrough science. From reimagining chronic care to building new business models, discover the mindse...

Tune in as Glenn Hunzinger, PwC’s Health Industries Leader, sits down with Nichole Montgomery, Shannon O’Shea, and Phil Sclafani to unpack the sweeping implications of the newly signed One Big Beautiful Bill Act (OBBBA). With nearly a third of the bill dedicated to healthcare, the team explores how this landmark legislation will reshape coverage, funding, and delivery across the payer, provider, a...

Tune in as Glenn Hunzinger, PwC’s Health Industries Leader, connects with Nick Donkar, PwC’s U.S. Health Services Deals Leader, and Roel Van den Akker, PwC’s Pharma and Life Sciences Deals Leader, to discuss the 2025 midyear deals outlook across health services and pharma and life sciences. They explore how macroeconomic trends, regulatory pressures, and evolving investment strategies are shaping...

Tune in as Glenn Hunzinger, PwC’s Health Industries Leader, and Phil Scalfani, PwC’s Pharmaceutical and Life Sciences Consulting Leader, discuss the Trump administration’s executive order on Most Favored Nation (MFN) drug pricing and its far-reaching implications across the healthcare ecosystem. They break down what MFN pricing could mean for pharmaceutical companies, payers, PBMs, and the broader...

Tune in as Glenn Hunzinger, PwC’s Health Industries Leader, connects with Matt Rich, PwC’s Pharma and Life Sciences R&D Leader, to unpack the recent disruption at the FDA and what it means for the pharmaceutical and biotech sectors. They discuss how companies can stay agile in the face of regulatory uncertainty, avoid preventable delays, and take practical steps to move programs forward with c...

Tune in as Glenn Hunzinger, PwC’s Health Industries Leader and Roel van den Akker, PwC’s Pharma and Life Sciences Deals Leader discuss the rapid rise of China’s biotech industry and what it means for U.S. pharmaceutical companies. They discuss the evolving role of Chinese biotech in the global innovation landscape and share perspectives on how U.S. pharmaceutical companies can thoughtfully assess...

Disclaimer: This episode was recorded on April 11th, 2025, and reflects the information available at the time of recording. As we know, America is in motion here, and so subsequent updates may not be reflected in this discussion as things continue to evolve and change.  Tune in as PwC specialists from across the health industry share their insights on how recent policy shifts under the Trump admin...

Tune in as PwC's Pharmaceutical & Life Sciences Advisory Leader, Greg Rotz reflects on key market dynamics and explores how pharma leaders can tackle challenges including the $400 billion patent cliff, increasing competition, drug pricing pressures, and transformative disruptions shaping the industry. Discussion highlights: Understanding the scale and implications of the upcoming patent c...

Tune in as PwC specialists discuss the 2025 healthcare outlook, reflecting on 2024’s significant events and exploring how payers and providers can navigate rising costs, scrutiny, AI advances, and policy shifts with resilience and adaptability.  Topics include: Medicare and Medicaid drive industry growth amid rising competition, market exits, M&A, AI adoption, and policy challenges. AI's...

Tune in to listen as PwC’s leaders Roel van den Akker and Nick Donkar provide insights into the 2024 deals landscape and offer a preview of what lies ahead. Topics include: Key topics include: A look back at M&A activity in health industries in 2024 The challenges and potential impediments that could affect deal volumes in the coming year How artificial intelligence and tech innovations are re...

Tune in as authors of PwC's U.S. Healthcare Climate Survey discuss key findings and provide insights into understanding healthcare organizations' responses to climate change, the integration of climate strategies, and the challenges faced in implementation. Key topics include: The survey's background, focus, and objectives that address the prioritization of climate strategies by hea...

Tune in as authors of PwC's U.S. Healthcare Consumer Insights and Engagement Survey discuss key findings and provide insights into understanding consumer concerns around healthcare costs, the adoption of tech-enabled healthcare, trust in the healthcare system and how we can take action.  Key topics include: The survey's background, focus and objectives that will address ongoing consumer...

How can medtech companies drive growth in today's market? Tune in as PwC specialists return to share key insights and strategies to help medtech companies invest in the capabilities required to compete in the future while aiming to exceed near-term expectations for growth and margin improvement. Key topics include: Challenges currently faced by medtech companies Reevaluating business models a...

What can the health industry expect from a second Trump administration? Tune in to hear what executives should watch over the next few months and years to come.  Key topics include: President-elect Trump's healthcare agenda and his focus on deregulation, flexibility and choice, and accessibility Potential implications for medicare, the ACA and IRA drug negotiations What to watch in the first...

Tune in as PwC specialists discuss best practices for securing a seat on an emerging company board.  Key topics include: Types of emerging companies Responsibilities of serving on emerging company boards Five strategies for securing a board position Importance of industry-specific expertise and continuous learning Speakers: Holly Reeves, Partner, Emerging Company Solutions Market Leader, Health In...